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We read with interest the recent systematic review and network meta-analysis by Wallis and 
colleagues [1]. We would like to draw attention to some concerns about the methodological 
approaches used in this paper. 
 
First, the specific objective and trial inclusion criteria are unclear, and therefore it is not clear 
why some trials were included and others were not. If the focus is high-risk and metastatic 
hormone-sensitive prostate cancer, then a number of additional trials in high-risk locally 
advanced disease would be eligible [2]. If the primary interest is metastatic disease, then it 
would have been better to restrict the primary analysis to those men. Unpublished trials have 
not been taken into account, and by excluding conference abstracts, the most up-to-date 
survival results of the CHAARTED trial [3] are overlooked. 
 
Second, there have been considerable advances in network meta-analysis methodology in 
recent years and a number of software packages are available to conduct these analyses. For 
their primary analysis, however, the authors relied on a simple “indirect comparison” 
(whereby two pairwise pooled log-hazard ratio estimates are subtracted from each other and 
their variances summed), which does not fully estimate model heterogeneity or inconsistency. 
The authors only carried out a “validation” analysis using a Bayesian network meta-analysis 
package for R. 
 
Third, in this particular network, the inclusion of two distinct treatment comparisons from the 
STAMPEDE trial [4] poses some particular challenges, in that the different treatment 
comparisons share common control-arm patients. In a network meta-analysis, this 
commonality must be considered to obtain results that take this correlation into account. 
There is no evidence that this was considered by the authors, and in fact the common control 
arm patients have been double-counted. 
 
Finally, in the network meta-analysis context, there are not yet robust or widely accepted 
methods for assessing treatment-subgroup interactions. We would therefore question the 
focus given to subgroup analyses and would certainly caution against the approach used here, 
namely the comparison of pooled treatment effects within subgroups defined by, for example, 
age and disease volume, without formal and appropriate tests for interaction. This can lead to 
considerable bias [5,6] that is likely to be further exacerbated when these effects are 
indirectly compared. More research is needed before subgroup analyses can be performed 
reliably in the context of network meta-analysis. 
 
Other factors not considered include changing prognosis or treatment effects over time and 
the potential impact of treatments used following disease progression. Many of these issues 
can only be addressed via collection of individual participant data. With all of this in mind, 
we would urge readers to treat the results and interpretation of this meta- analysis with some 
caution. 
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